Collegium Pharmaceutical Inc. (COLL) Upgraded to Hold by Zacks Investment Research
Collegium Pharmaceutical Inc. (NASDAQ:COLL) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Wednesday.
According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “
Several other research firms have also recently commented on COLL. Piper Jaffray Cos. set a $23.00 target price on Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Thursday, August 11th. Needham & Company LLC restated a “buy” rating and issued a $30.00 target price on shares of Collegium Pharmaceutical in a research report on Wednesday, September 14th. Gabelli started coverage on Collegium Pharmaceutical in a research report on Tuesday, September 13th. They issued a “buy” rating and a $25.00 target price on the stock. Finally, Jefferies Group restated a “buy” rating on shares of Collegium Pharmaceutical in a research report on Thursday, September 22nd. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $27.60.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/12/collegium-pharmaceutical-inc-coll-upgraded-to-hold-by-zacks-investment-research.html
Collegium Pharmaceutical (NASDAQ:COLL) traded up 3.00% on Wednesday, hitting $18.19. The stock had a trading volume of 378,623 shares. Collegium Pharmaceutical has a 12-month low of $8.24 and a 12-month high of $30.58. The company’s 50 day moving average price is $13.29 and its 200-day moving average price is $14.54. The company’s market cap is $427.97 million.
Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by $0.29. Equities research analysts anticipate that Collegium Pharmaceutical will post ($3.86) EPS for the current year.
In other news, Director John A. Fallon purchased 2,375 shares of the stock in a transaction dated Friday, August 12th. The shares were bought at an average cost of $10.59 per share, for a total transaction of $25,151.25. Following the transaction, the director now owns 2,375 shares in the company, valued at $25,151.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 37.93% of the company’s stock.
Institutional investors have recently modified their holdings of the stock. Neuberger Berman Group LLC purchased a new position in shares of Collegium Pharmaceutical during the second quarter valued at about $237,000. Swiss National Bank purchased a new position in shares of Collegium Pharmaceutical during the second quarter valued at about $212,000. California State Teachers Retirement System boosted its position in shares of Collegium Pharmaceutical by 76.0% in the second quarter. California State Teachers Retirement System now owns 28,395 shares of the specialty pharmaceutical company’s stock valued at $336,000 after buying an additional 12,258 shares during the period. Tocqueville Asset Management L.P. boosted its position in shares of Collegium Pharmaceutical by 18.2% in the second quarter. Tocqueville Asset Management L.P. now owns 51,900 shares of the specialty pharmaceutical company’s stock valued at $615,000 after buying an additional 8,000 shares during the period. Finally, Royal Bank of Canada boosted its position in shares of Collegium Pharmaceutical by 794.0% in the first quarter. Royal Bank of Canada now owns 11,300 shares of the specialty pharmaceutical company’s stock valued at $205,000 after buying an additional 10,036 shares during the period. Institutional investors own 62.13% of the company’s stock.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.